Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

Summary

This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are: * To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor * To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor

Timeline

Start

2007-07

Primary completion

2011-07

Completion

2011-10

Publications

• Results Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009: 5101

Drugs

Indications